A novel fibrin-based artificial ovary prototype resembling human ovarian tissue in terms of architecture and rigidity

Chiti, Maria Costanza; Dolmans, Marie-Madeleine; Mortiaux, Lucie; Zhuge, Flanco; Ouni, Emna; Shahri, Parinaz Asiabi Kohneh; Ruymbeke, Evelyne Van; Champagne, Sophie-Demoustier; Donnez, Jacques; Amorim, Christiani Andrade

doi:10.1007/s10815-017-1091-3

Cited by 81 publications

(70 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, fibrin matrices containing 50 mg/mL fibrinogen most closely resemble human ovarian cortex in terms of ultrastructure ( Fig. 4) and rigidity (Chiti et al 2018a). When using this matrix, follicle recovery rates after 1 week of xenografting to immunodeficient mice were between 22 and 35%, very similar to the results obtained after xenografting of human ovarian tissue (Nisolle et al 2000).…”

Section: D Matrix To Encapsulate Isolated Preantral Follicles and Ovsupporting

confidence: 72%

FERTILITY PRESERVATION: Construction and use of artificial ovaries

Dolmans

Amorim

2019

Reproduction

Self Cite

View full text Add to dashboard Cite

Increasing numbers of patients are now surviving previously fatal malignant diseases, so for women of childbearing age, fertility concerns are paramount once they are cured. However, the treatments themselves, namely chemo- and radiotherapy, can cause considerable damage to endocrine and reproductive functions, often leaving these women unable to conceive. When such gonadotoxic therapy cannot be postponed due to the severity of the disease or for prepubertal girls, the only way to preserve fertility is cryobanking their ovarian tissue for future use. Unfortunately, with some types of cancer, there is a risk of reimplanting malignant cells together with the frozen-thawed tissue, so it is not recommended. A safer approach involves grafting isolated preantral follicles back to their native environment inside a specially created transplantable artificial ovary for their protection. This bioengineered ovary must mimic the natural organ and therefore requires an appropriate scaffold to encapsulate not only isolated follicles, but also autologous ovarian cells, which are needed for follicles to survive and develop. Here we review the indications for use of this artificial ovary and advances in the field that are bringing us ever closer to clinical implementation.

show abstract

Section: D Matrix To Encapsulate Isolated Preantral Follicles and Ovsupporting

confidence: 72%

FERTILITY PRESERVATION: Construction and use of artificial ovaries

Dolmans

Amorim

2019

Reproduction

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although a few leukemic cells inside an artificial ovary may not lead to recurrent leukemia in an animal model, we need to reduce contamination of malignant cells to the utmost limits to ensure safety. The candidate basic materials for creating the scaffold are fibrin with thrombin and gelatin . Also, aimed to improve the outcome of OTT (not for artificial ovary), decellularized human extracellular tissue matrix (ECTM) was reported as scaffold .…”

Section: Future Possibilities Of Ovarian Tissue Transplantationmentioning

confidence: 99%

Current state and future possibilities of ovarian tissue transplantation

Takae

Suzuki

2019

Reprod Medicine & Biology

View full text Add to dashboard Cite

Background As a result of recent developments in cancer treatment, cancer survivorship and survivors' quality of life have been emphasized. Although ovarian tissue cryopreservation (OTC) is an experimental technique, it would be the sole technique for fertility preservation treatment for girls with malignant disease. Indeed, OTC requires ovarian tissue transplantation (OTT) for conception. As for OTC, there is room to investigate OTT. The present review focused on the current state and progress of OTT. Method The literature regarding OTT, which is currently under development, was reviewed. Main findings To improve the outcome of OTT, both efficacy and safety are important. Good surgical technique and the optimal site are important surgical factors, with orthotopic transplantation increasing. Treatment of growth factors, gonadotropins, antioxidants, apoptosis suppression factors, and cell therapy may improve the efficacy of OTT by inducing neo‐angiogenesis and preventing damage. Artificial ovaries, complete in vitro primordial follicle culture technique, and non‐invasive ovarian imaging techniques, such as optical coherence tomography, to select the best ovarian tissue are future possibilities. Conclusion Improving neo‐angiogenesis and preventing damage with optimization, as well as investigation of future techniques, may bring us to the next stage of a fertility preservation strategy.

show abstract

“…An extension of this is replacement for pubertal induction, and although this has been reported, there are significant concerns with that indication because the rapid estrogenization and early progesterone exposure are contrary to established principles of induction of puberty . In vitro follicle growth and the derivation of mature oocytes is advancing, as is the use of artificial ovary constructs, which can allow follicle development after removal of malignant cells . Although these and other areas require optimization and further development of the clinical applications is neessary, the successful development of this work around the world provides an excellent example of the translation of work from a rodent model through validation in a large mammal and then into clinical practice.…”

Section: Current Challenges and Future Possibilitiesmentioning

confidence: 99%

“…32 In vitro follicle growth and the derivation of mature oocytes is advancing, 33 as is the use of artificial ovary constructs, 34 which can allow follicle development after removal of malignant cells. 35 Although these and other areas require optimization and further development of the clinical applications is neessary, the successful development of this work around the world provides an excellent example of the translation of work from a rodent model through validation in a large mammal and then into clinical practice.…”

Section: Current Challeng E S and Future P Oss Ib Ilitie Smentioning

confidence: 99%

The development of ovarian tissue cryopreservation in Edinburgh: Translation from a rodent model through validation in a large mammal and then into clinical practice

Anderson

Baird

2019

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Ovarian tissue cryopreservation has developed rapidly from its origins in experiments in sheep in the 1990s, and is now becoming recognized as a standard, rather than experimental, procedure. This review summarizes the origins of the technique, and key milestones in its development since the first reported sheep pregnancy in 1994 to the first successful human pregnancy in 2004, and now to the first baby born following cryopreservation of prepubertal ovarian tissue. Many challenges remain to optimize this technique, to improve the survival of follicles within the reimplanted ovarian tissue, to improve its reproducibility and hence the success rate and the lifespan of the graft. The other key area remains the possibility of the grafted tissue containing malignant cells, most importantly in leukemia.

show abstract

A novel fibrin-based artificial ovary prototype resembling human ovarian tissue in terms of architecture and rigidity

Abstract: Of all the different fibrin matrix concentrations tested, F50/T50 emerged as the combination of choice in terms of ultrastructure and rigidity, most closely resembling human ovarian cortex.

Cited by 81 publications

References 39 publications

FERTILITY PRESERVATION: Construction and use of artificial ovaries

FERTILITY PRESERVATION: Construction and use of artificial ovaries

Current state and future possibilities of ovarian tissue transplantation

The development of ovarian tissue cryopreservation in Edinburgh: Translation from a rodent model through validation in a large mammal and then into clinical practice

Contact Info

Product

Resources

About